DDInter770 DDInter856
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
Fluvoxamine {u} (Compound) palliates {v} (Disease) endogenous depression
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Fluvoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tenecteplase
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Fluvoxamine (Compound) resembles Ridogrel (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene)
Fluvoxamine (Compound) upregulates CCNA1 (Gene)
Fluvoxamine (Compound) palliates endogenous depression (Disease)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene)
Fluvoxamine (Compound) causes Accommodation disorder (Side Effect)
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase
Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine